Acta Endicronologica
RomanianAcademy Romanian Academy
The Publishing House of the Romanian Academy The Publishing House of the Romanian Academy

ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
10.4183/aeb.
Author
Title
Abstract/Title
From through

  • Abstract view [Login to see FullText]

    General Endocrinology

    Catrina SB, Botusan I, Cucu C, Radian S, Caragheorgheopol A, Coculescu M

    IGF-1 levels in the cerebrospinal fluid in patients with acromegaly

    Acta Endo (Buc) 2008 4(2): 143-150 doi: 10.4183/aeb.2008.143

    Abstract
    IGF-I (Insulin like growth factor-I) plays a definitive role in the central nervous system (CNS) by modulating neuronal regeneration and survival. The local production of IGF-I in CNS has been demonstrated, but the contribution of circulating IGF-I transported through blood-brain barrier (BBB) has been just suggested in animals. There is currently no data available concerning IGF-I transport in CNS in humans. In order to investigate the passage of IGF-I over BBB in humans we have simultaneously measured the IGF-I and GH levels in serum and CSF in 25 patients with active acromegaly. IGF-I and GH levels in CSF were lower than in serum (2.2 ? 0.24 ng/mL vs 686.6 ? 46.83 ng/mL for IGF-I and 2.13 ? 0.627 mU/l vs 58.8 ? 15.86 mU/L for GH). However, both IGF-I and GH serum levels correlated with their CSF levels (r= 0.4, p<0.05 for IGF-I and r= 0.651, p= 0.006 for GH), suggesting that BBB is permeable for both hormones. In conclusion, we demonstrate the correlation of the IGF-I levels in serum and CSF, providing indirect evidence for IGF-I passage through BBB.
  • Abstract view [Login to see FullText]

    Notes & Comments

    Grigorescu F, Attaoua R, Ait El Mkadem S, Beleza S, Bohdanowicz-Pawlak A, Bosch Comas A, Boulton A, Brismar K, Catrina SB, Coculescu M, Escobar-Morreale H, Fica S, Gheorghiu M, Gomis R, Hanzu F, Jobling M, Khusnutdinova E, Milewicz A, Nosicov V, Novialis A, Pasqua, Muller-Wieland D

    Haplogendis initiative - SICA

    Acta Endo (Buc) 2009 5(1): 143-148 doi: 10.4183/aeb.2009.143

    Abstract
    In response to increasing interest of the European Commission on large-scale\r\ngenotyping for complex diseases, including variability in ethnic minorities in\r\nEurope (HEALTH-2009-4.3.3-1), at the end of 2008 we composed the\r\nHAPLOGENDIS consortium with partners from Russia and European countries. A\r\nfirst program (SICA) was proposed in cooperation with Russian Federal Agency for\r\nScience and Innovation, focusing on comparative population genetics on diseases\r\naccompanied by insulin resistance. Beside the specificity in analyzing the human\r\ngenome with SNP (single nucleotide polymorphism) and defining haplotype\r\nstructure of genes, the program rises new hypotheses which directly link\r\ncolonization of Europe at the Neolithic period from Eastern Ukraine or Anatolia\r\nwith the development of agriculture and major dietary and life style changes that\r\nmay have an impact on the genome. Although there will be many occasions to\r\nreview both genetic and clinical detailed aspects, this short note will expose some\r\nunifying ideas that joint these partners.
  • [Login to see FullText]

    Editorial

    Catrina SB, Brismar K

    Diabetic foot ulcers. Where we are and where are we going?

    Acta Endo (Buc) 2005 1(2): 213-218 doi: 10.4183/aeb.2005.213

    References
    1. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998; 176(2A Suppl):5S-10S.
    2. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990; 13(5):513-521. [CrossRef]
    3. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the nagement of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24(2):290-295. [CrossRef]
    4. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19(4):350-354. [CrossRef]
    5. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003; 90(2):133-146. [CrossRef]
    6. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomize [CrossRef]
    7. Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol 1995; 132(1):79-85. [CrossRef]
    8. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7(6):442-452. [CrossRef]
    9. Catrina SB, Lewitt M, Massambu C, Dricu A, Grunler J, Axelson M et al. Insulin-like growth factor-I receptor activity is essential for Kaposi?s sarcoma growth and survival. Br J Cancer 2005; 92(8):1467- 1474. [CrossRef]
    10. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9(5):604-613. [CrossRef]
    11. Hehenberger K, Heilborn JD, Brismar K, Hansson A. Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of l-lactate. Wound Repair Regen [CrossRef]
    12. Loot MA, Kenter SB, Au FL, van Galen WJ, Middelkoop E, Bos JD et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002; 81(3):153-160. [CrossRef]
    13. Hehenberger K, Hansson A. High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors. Cell Biochem Funct 1997; 15(3):197-201. [CrossRef]
    14. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44(11):1973-1988. [CrossRef]
    15. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42(6):801-813. [CrossRef]
    16. Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999; 22(1):147-151. [CrossRef]
    17. Ballard JL, Eke CC, Bunt TJ, Killeen JD. A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. J Vasc Surg 1995; 22(4):485-490. [CrossRef]
    18. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications 2002; 16(2):153-158. [CrossRef]
    19. Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg 2005; 92(1):24-32. [CrossRef]
    20. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58(6):2351-2366. [CrossRef]
    21. O?Toole EA, Marinkovich MP, Peavey CL, Amieva MR, Furthmayr H, Mustoe TA et al. Hypoxia increases human keratinocyte motility on connective tissue. J Clin Invest 1997; 100(11):2881-2891. [CrossRef]
    22. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003; 162(1):303-312. [CrossRef]
    23. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxiainducible factor-1alpha protein stability and function. Diabetes 2004; 53(12):3226-3232. [CrossRef]
    24. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxiainducible factor-1alpha. Genes Dev 2001; 15(19):2520-2532. [CrossRef]
    25. Breitbart AS, Laser J, Parrett B, Porti D, Grant RT, Grande DA et al. Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg 2003; 51(4):409-414. [CrossRef]
    26. Crombleholme TM. Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen 2000; 8(6):460-472. [CrossRef]
    27. Lee PY, Chesnoy S, Huang L. Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol 2004; 123(4):791-798. [CrossRef]
    28. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000; 8(6):480-493. [CrossRef]
    29. Sivan-Loukianova E, Awad OA, Stepanovic V, Bickenbach J, Schatteman GC. CD34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds. J Vasc Res 2003; 40(4):368-377. [CrossRef]


ISSN (print): 1841 - 0987     ISSN (online): 1843 - 066X  
Cookie Policy    Privacy Policy

Soluționarea alternativă a litigiilor Soluționarea online a litigiilor